Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know

Core Viewpoint - Wall Street anticipates flat earnings for Evolus, Inc. (EOLS) in the upcoming quarter, with revenues expected to increase, making the comparison between actual results and estimates crucial for stock price movement [1][2]. Earnings Expectations - The consensus estimate predicts a quarterly loss of $0.19 per share, unchanged from the previous year, while revenues are projected to be $67.82 million, reflecting an 11% increase year-over-year [3]. - The consensus EPS estimate has remained stable over the last 30 days, indicating a lack of significant reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Evolus is lower than the consensus estimate, resulting in an Earnings ESP of -2.70%, suggesting a bearish outlook from analysts [12]. - Despite the negative Earnings ESP, Evolus holds a Zacks Rank of 2 (Buy), complicating predictions of an earnings beat [12]. Historical Performance - Evolus has not surpassed consensus EPS estimates in the last four quarters, with the most recent quarter showing a significant miss of -166.67% [13][14]. Industry Comparison - CeriBell, Inc. (CBLL), another player in the medical products industry, is expected to report a loss of $0.43 per share, marking a year-over-year change of +76.8%, with revenues anticipated at $21.79 million, up 26.8% from the previous year [18]. - CeriBell's consensus EPS estimate has been revised 2.3% higher in the last 30 days, resulting in a positive Earnings ESP of +6.10%, indicating a likelihood of beating the consensus EPS estimate [19].